https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18999 Wed 27 Jul 2022 13:53:32 AEST ]]> Predictive algorithms for adjuvant therapy: transATAC https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12497 Sat 24 Mar 2018 08:15:55 AEDT ]]> Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13280 Sat 24 Mar 2018 08:15:16 AEDT ]]> Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11225 Sat 24 Mar 2018 08:11:14 AEDT ]]> Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5453 Sat 24 Mar 2018 07:48:12 AEDT ]]>